TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Period (PMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of ABBV-514
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Serum Concentration (Tmax) of ABBV-514
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Given Inappropriate Treatments
Endpoint domain: Adverse events/effects
Primary endpoint: level of anxiety perceived by patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total intraoperative consumption of sufentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Radiation Therapy Oncology Group grade 3 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Standing Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flanker Inhibitory Control Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dimensional Change Card Sorting Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: List Sorting Working Memory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with Daily Occupation (SDO-13)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occupational Balance Questionnaire (OBQ)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occupational values with pre-defined items (Oval-pd)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Uncontrolled hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate for operative cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target ulcer infection
Endpoint domain: Infections and infestations outcomes
Primary endpoint: Euploidy rate of resulting embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in cardiac effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tobacco smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose / Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants completing treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Biological Age Prediction Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of oxyhemoglobin desaturation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric Mean Titers (GMT) for SARS-CoV-2 Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroresponse to SARS-CoV-2 nAb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMT) for SARS-CoV-2 Anti-Spike Binding Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroresponse to Anti-Spike Binding Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum axial dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of the region of interest (ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of perfusion (f)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross sectional area of peripheral nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) response to visual stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall survival after R0/R1 resection
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analogue Scale of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F1 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of appropriate advice by the SC for mother and child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of safe advice by the SC for mother and child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Score in the Treatment Satisfaction Questionnaire (TSQM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants remaining flare-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sufentanil consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Face Pain Scale-Revised (FPS-R)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Perinatal Anxiety Screening Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of grade ≥ 3 haematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of grade ≥ 3 gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: magnitude of microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: magnitude of brachial artery endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: magnitude of microvascular endothelin-1 mediated constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Disease activity remission status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Modifying Anti-Rheumatic Drug (DMARD)-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic score (van der Heijde modified Sharp score (vdHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effect reports
Endpoint domain: Adverse events/effects
Primary endpoint: Post-randomization drop out
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Latency and amplitude of blink reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Active Knee Extension Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Excessive Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Complete Remission (CRc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration [C(max)] of PBI-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to the time of the last measurable concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of PBI-200 from time zero to infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Engagement with Resources
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: p16INK4a level changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ-specific protein expression change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in TNmAS-MALL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Total Maximal Chorea (TMC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Maximum Tolerated dose of RC108
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Morning Peak Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of TTR-CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants experiencing Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Right ventricle diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricle fractional area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricle systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid consumption at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life by Short Form 36 (SF-36) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of MET protein overexpression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in modified Friedreich Ataxia Rating Scale (mFARS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for the Assessment and Rating of Ataxia (SARA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FA Activities of Daily Living (ADL) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Upright Stability (US) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response as measured by modified Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate against T. trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Calf Muscle Oxygen Saturation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral Treatment Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients without grade 2 or more fibrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients without radio-induced sarcoma
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Clindamycin Resistance Antibiotic Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bone Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency and type of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability and feasibility of EGD-SC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visuospatial memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial rotation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tele-healthcare Satisfaction Questionnaire - Wearable Technology (TSQ-WT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Information Transfer Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: National Aeronautics and Space Administration (NASA) Task Load Index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient-Reported Pain Intensity and Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in renal allograft interstitial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients alive
Endpoint domain: Mortality/survival
Primary endpoint: motor skill consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IASI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech and language development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: remission of nephrotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 50% Reduction in Tumor Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Short-term mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bladder Compliance Average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average Number of 24 Hour Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mutation profile results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ELD
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate at 35 days of simultaneous reduction of LVESVI and LVEDVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: irregularity of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported impacts of malocclusion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pulmonary embolism recurrence diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Cryotherapy related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diaphragmatic thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical outcomes of patients undergoing anesthesia and/or critical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon dioxide emission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-perception of voice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes felt by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Numeric Pain Scale Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalization rate of serum biomarker at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Key burdens related to the disease or treatments
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Life impacts of those burdens for patient/family
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: post-infection symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the medical device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of serum Fetuin-A values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of the disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC at steady state between Week 16 and Week 19 (AUCtau_ss) of ABP 234
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Daily Cornstarch Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to NCCN guidelines for clinical encounters
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to NCCN guidelines for annual mammogram
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Arithmetic fluency 1-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, severity and nature of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, severity and nature of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in vital sign parameter (blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-meter backwards walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in the Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median number of rBPM measures obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women monitoring blood pressure (BP) according to ACOG guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of Severe Hypertension events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in score Overactive Bladder Questionnaire-Symptom Bother Scale (OAB-q-SS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General Questionnaire (FACIT-TS-G)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degree of RAS assessed by angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical outcome by American shoulder elbow score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative index of XTR004 PET myocardial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in pVO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Coronary Heart Disease Death-Based Major Adverse Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patients with cancer cell/macrophage hybrid cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient mental wellbeing (quantitative)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction (quantitative)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CRA recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observational Gait Scale (OGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times chaplain is requested by patient or provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usefulness, feasibility, and reception of screening mechanism for GCAC staff
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of meetings/conversations pertaining to each theme identified
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of Age-related Macular Degeneration (AMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of treatment-emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change from baseline in lactate dehydrogenase (LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Number of PCP Visits Where Ppt Was Referred to Diabetes Prevention Program Within 30 Days of Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of PCP Visits Where Ppt Was Prescribed Metformin Within 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of PCP Visits Where Ppt Was Referred to Medical Nutrition Therapy Within 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention